These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27244371)

  • 1. Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
    Markovic S; Dragomir S; Walcher D; Bernhardt P; Imhof A; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2016 Nov; 27(7):561-5. PubMed ID: 27244371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
    Diletti R; Ishibashi Y; Felix C; Onuma Y; Nakatani S; van Mieghem NM; Regar E; Valgimigli M; de Jaegere PP; van Ditzhuijzen N; Fam JM; Ligthart JMR; Lenzen MJ; Serruys PW; Zijlstra F; Jan van Geuns R
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):58-69. PubMed ID: 27896897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R.
    Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C
    EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
    Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
    Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
    BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
    EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.
    Kugler C; Markovic S; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2017 Mar; 28(2):120-125. PubMed ID: 27845998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
    Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions.
    Shin ES; Ann SH; Balbir Singh G; Lim KH; Kleber FX; Koo BK
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):193-200. PubMed ID: 26423017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.